Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects

NCT01232543 is registered in ClinicalTrials.gov with Fougera Pharmaceuticals Inc. as lead sponsor.

NCT NCT01232543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01232543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects
Lead sponsor
Fougera Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
November 30, 2011
Enrollment
114 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis